FDA-cleared profile

Brainomix 360 e-CTA

Brainomix Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.

Clinical role
CTA visualization and analysis support for reviewing hemispheric vessel-density differences, contrast intensity, estimated phase, and registered overlays; the results support but do not replace trained clinical interpretation.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Brain CT angiography images acquired through DICOM-compliant imaging devices and transferred from a PACS or other DICOM-compliant device.
  • Who uses it?Intended users: Trained professionals, including physicians and medical technicians, with interpretation by a trained clinician responsible for care decisions.
  • What does the software produce?Output: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
  • What is its most important limitation?Key limitation: The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.

Clinical takeaway. Clinical role: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.

Evidence takeaway. Evidence from the reviewed source record: K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
CTA visualization and analysis support for reviewing hemispheric vessel-density differences, contrast intensity, estimated phase, and registered overlays; the results support but do not replace trained clinical interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Brain CT angiography images acquired through DICOM-compliant imaging devices and transferred from a PACS or other DICOM-compliant device.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Brain CTA visualization, post-processing, and clinical review within a hospital imaging network, PACS workstation, or connected web interface.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained professionals, including physicians and medical technicians, with interpretation by a trained clinician responsible for care decisions.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Vessel delineation Dice

0.955 Dice similarity coefficient

  • EndpointVessel delineation Dice across the full standalone-performance sample
  • Population308 US brain CTA scans from clinical sites
  • Tested versionBrainomix 360 e-CTA configuration described in K242123

Parenchyma-mask Dice

0.999 Dice similarity coefficient

  • EndpointParenchyma mask Dice across the full standalone-performance sample
  • Population308 US brain CTA scans from clinical sites
  • Tested versionBrainomix 360 e-CTA configuration described in K242123

K242123 Brainomix 360 e-CTA standalone performance validation

  • DesignRetrospective standalone performance study comparing AI/ML vessel delineation and parenchyma masking with the stated reference process across clinical CTA scans.
  • Population308 US brain CTA scans: 179 from Boston Medical Centre or referring Massachusetts hospitals and 129 from Mayo Clinic Rochester; scanners included Siemens, GE, Philips, and Canon/Toshiba systems, with demographic, site, scanner, and stenosis stratifications.
  • Scopeexact submission
  • Tested versionBrainomix 360 e-CTA configuration described in K242123
  • Samplen=308
  • IndependenceSponsor or vendor study

K242123

Manufacturer-submitted FDA evidence; the named clinical sources do not make this an independent investigator study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K242123. This is not a comprehensive safety clearance and does not exclude family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Brain CT angiography images acquired through DICOM-compliant imaging devices and transferred from a PACS or other DICOM-compliant device.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K242123: Brainomix 360 e-CTA

  2. Routing

    Source context, not route validation: The exact submission can receive CTA scans from a PACS through DICOM, send results and images to PACS through DICOM, and expose results through a web interface on a machine within the hospital network and firewall; local routing, worklist, email, viewer, and failure behavior require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K242123: Brainomix 360 e-CTA

  3. AI processing

    Source context, not route validation: The exact submission runs on standard off-the-shelf physical or virtual server hardware and is accessed through a hospital network and firewall or LAN connection; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K242123: Brainomix 360 e-CTA

  4. Returned objects

    Source context, not route validation: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K242123: Brainomix 360 e-CTA

  5. Viewer/worklist/report

    Unresolved route: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K242123: Brainomix 360 e-CTA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact submission runs on standard off-the-shelf physical or virtual server hardware and is accessed through a hospital network and firewall or LAN connection; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission can receive CTA scans from a PACS through DICOM, send results and images to PACS through DICOM, and expose results through a web interface on a machine within the hospital network and firewall; local routing, worklist, email, viewer, and failure behavior require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
  • Product family
  • Checked 2026-10-25

Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.

Monitoring
Monitor CTA transfer and protocol eligibility, MCA-only interpretation of vessel-density asymmetry, image-quality and registration failures, compressed-preview versus diagnostic-viewer use, PACS/web/email delivery, failed or repeated analyses, reader overrides, downtime, updates, complaints, and exact-submission recalls.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Family delivery and DICOM compatibility

Brainomix's current FAQ says Brainomix 360 Stroke results are typically available within 1-2 minutes and delivered via PACS, email, mobile app, or web browser; it supports major scanner and PACS manufacturers through standard DICOM and engineers test connections before go-live. This is family-level context and does not establish exact K242123 latency or configuration.

product family · checked 2026-09-07

Family installation and user training

Brainomix's current FAQ describes a managed appliance on virtualized cloud or physical hardware, with vendor-led installation, scanner/PACS connection, protocol setup, and go-live testing alongside hospital IT; it also describes group training and multilingual manuals for clinical users. Exact K242123 terms and curriculum were not established.

product family · checked 2026-09-07

Exact DICOM/PACS and notification workflow

The FDA packet describes DICOM transfer to and from PACS, hospital-network web viewing, and compressed email previews that are not diagnostic; confirm local routing, diagnostic-viewer access, notification policy, and failure recovery during qualification.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242123
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-06
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or exact contract unit for K242123 was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Brainomix 360 reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No Brainomix page naming coding or payment for this product was found. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The FDA indication requires trained professionals; the official FAQ describes family training but does not establish an exact K242123 curriculum or competency assessment.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K242123: Brainomix 360 e-CTA

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Brainomix 360 e-CTA model card (K242123)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Brainomix 360 official FAQ

    Brainomix Limited - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, security, training

  8. Brainomix 360 official FAQ

    Brainomix Limited - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, training

  9. openFDA exact recall query for K242123

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K242123 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K221564

Brainomix 360 e-ASPECTS

Brainomix Limited

Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.

Modality
CT/CTA
Anatomy
Brain
Decision
2023-02-23
FDA-cleared K193289

FastStroke, CT Perfusion 4D

GE Medical Systems SCS

Authorized purpose: Analyzes CT data to display head and neck vasculature and CT perfusion to generate regional blood-flow, blood-volume, mean-transit-time, and capillary-permeability images.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-11-12
FDA-cleared K192962

icobrain-ctp

Icometrix NV

Authorized purpose: Analyzes and communicates dynamic CT-perfusion datasets.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-02-28
FDA-cleared K181247

Vitrea CT Brain Perfusion

Vital Images, Inc.

Authorized purpose: Non-invasive post-processing for brain perfusion that calculates CBF, CBV, bolus timing/TTP, and MTT.

Modality
CT/CTA
Anatomy
Brain
Decision
2018-11-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history